RESUMO
BACKGROUND: Nonoperative management after neoadjuvant treatment in low rectal cancer enables organ preservation and avoids surgical morbidity. Our aim is to compare oncological outcomes in patients with clinical complete response in watch and wait strategy with those who received neoadjuvant therapy followed by surgery with a pathological complete response. METHODS: Patients with non-metastatic rectal cancer after neoadjuvant treatment with clinical complete response in watch and wait approach (group 1, n = 26) and complete pathological responders (ypT0N0) after chemoradiotherapy and surgery (group 2, n = 22), between January 2011 and October 2018, were included retrospectively, and all of them evaluated and followed in a multidisciplinary team. A comparative analysis of local and distant recurrence rates and disease-free and overall survival between both groups was carried out. Statistical analysis was performed using log-rank test, Cox proportional hazards regression model, and Kaplan-Meier curves. RESULTS: No differences were found between patient's demographic characteristics in both groups. Group 1: distance from the anal verge mean 5 cm (r = 1-12), 10 (38%) stage III, and 7 (27%) circumferential resection margin involved. The median follow-up of 47 months (r = 6, a 108). Group 2: distance from the anal verge mean 7 cm (r = 2-12), 16 (72%) stage III, and 13 (59%) circumferential resection margin involved. The median follow-up 49.5 months (r = 3, a 112). Local recurrence: 2 patients in group 1 (8.3%) and 1 in group 2 (4.8%) (p = 0.6235). Distant recurrence: 1 patient in group 1 (3.8%) and 3 in group 2 (19.2%) (p = 0.2237). Disease-free survival: 87.9% in group 1, 80% in group 2 (p = 0.7546). Overall survival: 86% in group 1 and 85% in group 2 (p = 0.5367). CONCLUSION: Oncological results in operated patients with pathological complete response were similar to those in patients under a watch and wait strategy mediating a systematic and personalized evaluation. Surgery can safely be deferred in clinical complete responders.
Assuntos
Terapia Neoadjuvante , Neoplasias Retais , Quimiorradioterapia , Humanos , Recidiva Local de Neoplasia/terapia , Prognóstico , Neoplasias Retais/terapia , Estudos Retrospectivos , Resultado do Tratamento , Conduta ExpectanteRESUMO
El mesotelioma maligno es un tumor que se presenta en relación 1: 4000 pacientes autopsiados por neoplasias malignas. La localización pericárdica es la menos frecuente, constituyendo menos del 2 por ciento del total de tumores cardíacos. Se presenta un caso en el que el tumor produjo un síndrome de taponamiento cardíaco, sin ser diagnosticado en vida a pesar de efectuarse una biopsia pericárdica subxifoidea. El paciente murió bruscamente, halládose en la autopsia dicho tumor infiltrando la aurícula derecha y haciendo protusión en la cavidad, englobando la arteria coronaria derecha. Esto último podría ser responsable de la muerte. Se comparan los hallazgos clínicos y patológicos con 30 casos extraídos de la literatura reciente
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Mesotelioma/patologia , Neoplasias Cardíacas/patologia , Pericárdio/patologia , Evolução Fatal , Neoplasias Pulmonares/secundário , Invasividade Neoplásica , Neoplasias Pleurais/patologiaRESUMO
El mesotelioma maligno es un tumor que se presenta en relación 1: 4000 pacientes autopsiados por neoplasias malignas. La localización pericárdica es la menos frecuente, constituyendo menos del 2 por ciento del total de tumores cardíacos. Se presenta un caso en el que el tumor produjo un síndrome de taponamiento cardíaco, sin ser diagnosticado en vida a pesar de efectuarse una biopsia pericárdica subxifoidea. El paciente murió bruscamente, halládose en la autopsia dicho tumor infiltrando la aurícula derecha y haciendo protusión en la cavidad, englobando la arteria coronaria derecha. Esto último podría ser responsable de la muerte. Se comparan los hallazgos clínicos y patológicos con 30 casos extraídos de la literatura reciente (AU)
